About STAAR Surgical Company
https://www.staar.comSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.
CEO
Stephen C. Farrell CFA
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1992-05-18 | Reverse | 1:2 |
| 1990-11-01 | Reverse | 1:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 143
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Wells Fargo
Equal Weight
Stephens & Co.
Equal Weight
William Blair
Market Perform
Sidoti & Co.
Neutral
Mizuho
Neutral
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BROADWOOD CAPITAL INC
Shares:13.52M
Value:$295M
BLACKROCK INC.
Shares:7.49M
Value:$163.41M
BLACKROCK, INC.
Shares:7.26M
Value:$158.39M
Summary
Showing Top 3 of 264
About STAAR Surgical Company
https://www.staar.comSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $94.73M ▼ | $59.38M ▼ | $8.88M ▲ | 9.38% ▲ | $0.18 ▲ | $26.44M ▲ |
| Q3-2025 | $44.32B ▲ | $57.52B ▲ | $-16.81B ▼ | -37.93% | $-0.34 | $0 ▲ |
| Q2-2025 | $44.32M ▲ | $62.76M ▼ | $-16.81M ▲ | -37.93% ▲ | $-0.34 ▲ | $-22.74M ▲ |
| Q1-2025 | $42.59M ▼ | $85.41M ▲ | $-54.21M ▼ | -127.29% ▼ | $-1.1 ▼ | $-32.4M ▼ |
| Q4-2024 | $48.95M | $59.56M | $-34.23M | -69.92% | $-0.69 | $-25.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $192.66M ▼ | $456.36M ▼ | $102.58M ▼ | $353.78M ▼ |
| Q3-2025 | $189.88B ▲ | $437.78B ▲ | $101.21B ▲ | $336.57B ▲ |
| Q2-2025 | $189.88M ▼ | $437.78M ▼ | $101.21M ▼ | $336.57M ▼ |
| Q1-2025 | $222.76M ▼ | $457.36M ▼ | $107.39M ▼ | $349.97M ▼ |
| Q4-2024 | $230.49M | $509.52M | $112.19M | $397.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.88M ▼ | $2.67M ▼ | $5.28M ▲ | $983K ▲ | $9.02M ▲ | $1.78M ▲ |
| Q3-2025 | $70.95M ▲ | $32.96M ▲ | $0 ▼ | $0 ▲ | $-22.98M ▼ | $0 ▲ |
| Q2-2025 | $-16.81M ▲ | $-27.25M ▼ | $25.12M ▼ | $-4.54M ▼ | $-5.98M ▼ | $-29.04M ▼ |
| Q1-2025 | $-54.21M ▼ | $-5.73M ▼ | $35.35M ▲ | $-948K ▼ | $28.95M ▲ | $-7.2M ▼ |
| Q4-2024 | $-34.23M | $642K | $-19.5M | $-110K | $-19.84M | $-5.08M |
Revenue by Products
| Product | Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 |
|---|---|---|---|---|
 Implantable Collamer Lenses | $100.00M ▲ | $90.00M ▼ | $150.00M ▲ | $40.00M ▼ |
 Other Surgical Products | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2018 | Q1-2019 | Q2-2019 | Q3-2019 |
|---|---|---|---|---|
 CHINA | $10.00M ▲ | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 JAPAN | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 KOREA REPUBLIC OF | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Countries | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Stephen C. Farrell CFA
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1992-05-18 | Reverse | 1:2 |
| 1990-11-01 | Reverse | 1:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 143
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Wells Fargo
Equal Weight
Stephens & Co.
Equal Weight
William Blair
Market Perform
Sidoti & Co.
Neutral
Mizuho
Neutral
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BROADWOOD CAPITAL INC
Shares:13.52M
Value:$295M
BLACKROCK INC.
Shares:7.49M
Value:$163.41M
BLACKROCK, INC.
Shares:7.26M
Value:$158.39M
Summary
Showing Top 3 of 264